PLUVICTO DIN 02530198
Status: Marketed
Holder: NOVARTIS PHARMACEUTICALS CANADA INC
Molecule: LUTETIUM (177LU) VIPIVOTIDE TETRAXETAN
Health Canada record
| Active ingredient(s) | LUTETIUM (177LU) VIPIVOTIDE TETRAXETAN 1000 MBq |
|---|---|
| Dosage form | Solution |
| Route | Intravenous |
| Schedule | SCHEDULE C |
| Class | Radiopharmaceutical |
| ATC | V10XX05 LUTETIUM (177LU) VIPIVOTIDE TETRAXETAN |
| Original market date | 07-Nov-2022 |
| Current status date | 02-Sep-2024 |
| Source | Health Canada DPD |
Establishment licence of the holder
Novartis Pharmaceuticals Canada Inc — licence 100273, currently licensed, last inspection rating C (2025-01-14).
No Canadian shortage report is currently matched to this DIN.
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 32790 | 2024-02-28 | New Drug Submission (NDS) | Administrative - Change in Product Ownership |
| 28832 | 2022-08-25 | New Drug Submission (NDS) |